/GNMLF

GNMLF Stock - Genomma Lab Internacional, S.A.B. de C.V.

Q: What is the analyst price target for GNMLF?

Analyst price target information is not currently available for GNMLF.

Q: What is GNMLF's market cap?

Market capitalization information is not currently available for GNMLF.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$1.06+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.17

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for GNMLF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.35

52W High$1.43

52W Low$0.93

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$892.41M	$969.48M	$862.36M	$754.10M	$696.10M
Gross Profit	$572.23M	$593.52M	$521.09M	$465.65M	$431.01M
Gross Margin	64.1%	61.2%	60.4%	61.7%	61.9%
Operating Income	$188.13M	$188.96M	$169.35M	$145.92M	$147.24M
Net Income	$1.49B	$63.89M	$71.22M	$63.68M	$70.44M
Net Margin	167.3%	6.6%	8.3%	8.4%	10.1%
EPS	$1.53	$0.07	$0.07	$0.06	$0.07

Company Overview

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.

Visit Website

Earnings History & Surprises

GNMLF

Beat Rate

39%

Last 18 quarters

Avg Surprise

+273.7%

EPS vs Estimate

Beats / Misses

7/11

Last 12 quarters

Latest EPS

$0.00

Q4 2025

EPS Surprise History

Q1 24

-160.8%

$-0.01vs$0.01

Q2 24

+10.2%

$0.02vs$0.02

Q3 24

+59.1%

$0.04vs$0.02

Q4 24

+29.3%

$0.04vs$0.03

Q1 25

+1625.9%

$0.48vs$0.03

Q2 25

+2368.7%

$0.51vs$0.02

Q3 25

+1182.1%

$0.36vs$0.03

Q4 25

-95.3%

$0.00vs$0.03

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 28, 2026	—	—	—	—
Q1 2026	Feb 24, 2026	—	—	—	—
Q4 2025	Oct 31, 2025	$0.03	$0.00	-95.3%	✗ MISS
Q3 2025	Jul 23, 2025	$0.03	$0.36	+1182.1%	✓ BEAT
Q2 2025	Apr 30, 2025	$0.02	$0.51	+2368.7%	✓ BEAT
Q1 2025	Feb 27, 2025	$0.03	$0.48	+1625.9%	✓ BEAT
Q4 2024	Oct 23, 2024	$0.03	$0.04	+29.3%	✓ BEAT
Q3 2024	Jul 24, 2024	$0.02	$0.04	+59.1%	✓ BEAT
Q2 2024	Apr 24, 2024	$0.02	$0.02	+10.2%	✓ BEAT
Q1 2024	Feb 22, 2024	$0.01	$-0.01	-160.8%	✗ MISS
Q3 2023	Sep 29, 2023	$0.02	$0.02	-7.7%	✗ MISS
Q2 2023	Jun 29, 2023	$0.02	$0.03	+10.5%	✓ BEAT
Q1 2023	Mar 30, 2023	$0.02	$0.02	-1.2%	✗ MISS
Q1 2023	Feb 22, 2023	$0.39	$0.27	-30.8%	✗ MISS
Q4 2022	Oct 26, 2022	$0.43	$0.40	-7.0%	✗ MISS
Q3 2022	Jul 27, 2022	$0.43	$0.40	-7.0%	✗ MISS
Q2 2022	Apr 27, 2022	$0.45	$0.34	-24.4%	✗ MISS
Q1 2022	Feb 23, 2022	$0.41	$0.36	-12.2%	✗ MISS
Q4 2021	Oct 27, 2021	$0.42	$0.39	-7.1%	✗ MISS
Q3 2021	Jul 28, 2021	$0.40	$0.38	-5.0%	✗ MISS

Frequently Asked Questions about GNMLF

What is GNMLF's current stock price?

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) is currently trading at $1.06 per share. The stock has moved +0.00% today.

What is the analyst price target for GNMLF?

No analyst price targets are currently available for this stock.

What sector is Genomma Lab Internacional, S.A.B. de C.V. in?

Genomma Lab Internacional, S.A.B. de C.V. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is GNMLF's market cap?

Genomma Lab Internacional, S.A.B. de C.V. has a market capitalization of $1.06 billion, making it a small-cap company.

Does GNMLF pay dividends?

No, Genomma Lab Internacional, S.A.B. de C.V. does not currently pay a dividend to shareholders.